Skip to content

Inspection Record

Orean Personal Care Ltd — FDA 483 Findings

US FDAInspected 2026-02-20Published 2026-11-12 8 findingsProcess validationComputer system validationEquipment and facilityMaterial and supplier controlOther quality systemLaboratory and QC controlsDeviation, CAPA, and investigation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

2Computer system validation

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

3Equipment and facility

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

4Material and supplier control

Written procedures are lacking which describe in sufficient detail the receipt, sampling and testing of components of drug products.

5Other quality system

The responsibilities and procedures applicable to the quality contro] unit are not in writing and/or fully followed.

6Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, test procedures designed to assure that components of drug product, in-process materials, and drug products conform to appropriate standards of identity, strength, quality and purity.

7Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

8Material and supplier control

There wasa failure to handle and store components of drug product at all times in a manner to prevent contamination.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-12. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Orean Personal Care Ltd findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.